SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
Clinical trial NCT02301039 · COMPLETED
Trial details
- NCT number
- NCT02301039
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-01
- Primary completion
- 2020-07-01
- Enrollment
- 144
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.